Drug intelligence / Profile preview

DXC010

Development stage: Preclinical
Lead developer: Hangzhou DAC Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

DXC010 is an antibody-drug conjugate (ADC) being developed by Hangzhou DAC Biotech for the treatment of solid tumors. As an ADC, it is designed to leverage the specificity of a monoclonal antibody to deliver a potent cytotoxic payload directly to cancer cells, thereby increasing therapeutic efficacy while reducing off-target effects. The specific molecular target and the chemical nature of the linker and payload have not been publicly disclosed by the developer. DXC010 is currently in the preclinical stage of development, representing part of DAC Biotech's expanding portfolio of next-generation ADC candidates.

Beyond the preview

Go deeper on DXC010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DXC010.

Explore the full profile